Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress
Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update
Kindred Companion Sciences Unveils First Dogs Genetically Edited to Remove the Major Dog Allergen
Promising Medical Stocks To Research - August 3rd
Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results
Restart Life Sciences Strengthens Operational Infrastructure to Scale "Better-for-You" Portfolio | NMLSF Stock News